| __timestamp | BioMarin Pharmaceutical Inc. | GSK plc |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 8246000000 |
| Thursday, January 1, 2015 | 402271000 | 9232000000 |
| Friday, January 1, 2016 | 476593000 | 9366000000 |
| Sunday, January 1, 2017 | 554336000 | 9672000000 |
| Monday, January 1, 2018 | 604353000 | 9915000000 |
| Tuesday, January 1, 2019 | 680924000 | 11402000000 |
| Wednesday, January 1, 2020 | 737669000 | 11456000000 |
| Friday, January 1, 2021 | 759375000 | 10975000000 |
| Saturday, January 1, 2022 | 854009000 | 8372000000 |
| Sunday, January 1, 2023 | 937300000 | 9385000000 |
| Monday, January 1, 2024 | 1009025000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. Over the past decade, from 2014 to 2023, GSK plc and BioMarin Pharmaceutical Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. GSK plc, a global healthcare giant, consistently reported higher SG&A expenses, peaking in 2020 with a 39% increase from 2014. In contrast, BioMarin, a leader in rare disease therapies, saw a remarkable 210% rise in SG&A expenses over the same period, reflecting its aggressive growth strategy. Notably, 2022 marked a pivotal year for both companies, with GSK's expenses dropping by 27% from the previous year, while BioMarin continued its upward trajectory. This analysis underscores the strategic financial decisions shaping the future of these pharmaceutical leaders.
Merck & Co., Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Pfizer Inc. vs GSK plc
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Gross Profit Analysis: Comparing GSK plc and BioMarin Pharmaceutical Inc.
Breaking Down SG&A Expenses: GSK plc vs ADMA Biologics, Inc.
GSK plc vs Amicus Therapeutics, Inc.: SG&A Expense Trends
GSK plc and Merus N.V.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: GSK plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation